Impact of the hepatoselective glucokinase activator TTP399 on ketoacidosis during insulin withdrawal in people with type 1 diabetes.

Autor: Klein KR; Division of Endocrinology and Metabolism, Department of Medicine, University of North Carolina School of Medicine, Chapel Hill, North Carolina, USA., Boeder SC; Division of Endocrinology and Metabolism, Department of Medicine, University of California, San Diego, La Jolla, California, USA., Freeman JLR; vTv Therapeutics LLC, High Point, North Carolina, USA., Dunn I; vTv Therapeutics LLC, High Point, North Carolina, USA., Dvergsten C; vTv Therapeutics LLC, High Point, North Carolina, USA., Madduri S; Division of Endocrinology and Metabolism, Department of Medicine, University of North Carolina School of Medicine, Chapel Hill, North Carolina, USA., Giovannetti ER; Division of Endocrinology and Metabolism, Department of Medicine, University of California, San Diego, La Jolla, California, USA., Valcarce C; vTv Therapeutics LLC, High Point, North Carolina, USA., Buse JB; Division of Endocrinology and Metabolism, Department of Medicine, University of North Carolina School of Medicine, Chapel Hill, North Carolina, USA., Pettus JH; Division of Endocrinology and Metabolism, Department of Medicine, University of California, San Diego, La Jolla, California, USA.

Publikováno v: Diabetes, obesity & metabolism [Diabetes Obes Metab] 2022 Aug; Vol. 24 (8), pp. 1439-1447. Date of Electronic Publication: 2022 Jun 04.

The SimpliciT1 Study: A Randomized, Double-Blind, Placebo-Controlled Phase 1b/2 Adaptive Study of TTP399, a Hepatoselective Glucokinase Activator, for Adjunctive Treatment of Type 1 Diabetes.

Autor: Klein KR; Division of Endocrinology and Metabolism, University of North Carolina School of Medicine, Chapel Hill, NC klara_klein@med.unc.edu., Freeman JLR; vTv Therapeutics LLC, High Point, NC., Dunn I; vTv Therapeutics LLC, High Point, NC., Dvergsten C; vTv Therapeutics LLC, High Point, NC., Kirkman MS; Division of Endocrinology and Metabolism, University of North Carolina School of Medicine, Chapel Hill, NC., Buse JB; Division of Endocrinology and Metabolism, University of North Carolina School of Medicine, Chapel Hill, NC., Valcarce C

Publikováno v: Diabetes care [Diabetes Care] 2021 Apr; Vol. 44 (4), pp. 960-968. Date of Electronic Publication: 2021 Feb 23.

Targeting hepatic glucokinase to treat diabetes with TTP399, a hepatoselective glucokinase activator.

Autor: Vella A; Division of Endocrinology and Diabetes, Department of Medicine, Mayo Clinic, Rochester, MN 55905, USA., Freeman JLR; vTv Therapeutics Inc. and vTv Therapeutics LLC, High Point, NC 27265, USA., Dunn I; vTv Therapeutics Inc. and vTv Therapeutics LLC, High Point, NC 27265, USA., Keller K; vTv Therapeutics Inc. and vTv Therapeutics LLC, High Point, NC 27265, USA., Buse JB; Division of Endocrinology and Metabolism, Department of Medicine, University of North Carolina School of Medicine, Chapel Hill, NC 27599, USA., Valcarce C; vTv Therapeutics Inc. and vTv Therapeutics LLC, High Point, NC 27265, USA. cvalcarce@vtvtherapeutics.com.

Publikováno v: Science translational medicine [Sci Transl Med] 2019 Jan 16; Vol. 11 (475).

Recent drug development of dorzagliatin, a new glucokinase activator, with the potential to treat Type 2 diabetes: A review study.

Autor: Jiang, Yu^1,2 (AUTHOR), Wang, Luyao^1,2 (AUTHOR), Dong, Zhenhua^1,2 (AUTHOR), Xia, Baotian^1,2 (AUTHOR), Pang, Shuguang^1,2 (AUTHOR) shuguangpang@163.com

Publikováno v: Journal of Diabetes. Jun2024, Vol. 16 Issue 6, p1-13. 13p.

Neuroinflammation of Microglial Regulation in Alzheimer's Disease: Therapeutic Approaches.

Autor: Chen, Haiyun¹ (AUTHOR) yx07230chy@126.com, Zeng, Yuhan^2,3,4,5 (AUTHOR) ted20192022@outlook.com, Wang, Dan^2,3,4,5 (AUTHOR), Li, Yichen⁶ (AUTHOR) lycoco2021@163.com, Xing, Jieyu¹ (AUTHOR), Zeng, Yuejia¹ (AUTHOR), Liu, Zheng⁷ (AUTHOR) liuzheng8709@fosu.edu.cn, Zhou, Xinhua⁸ (AUTHOR) xinhuazhou9901@163.com, Fan, Hui^2,3,4,5 (AUTHOR) xinhuazhou9901@163.com

Publikováno v: Molecules. Apr2024, Vol. 29 Issue 7, p1478. 24p.